Hypoxic microenvironment-induced exosomes confer temozolomide resistance in glioma through transfer of pyruvate kinase M2
Abstract Objective Glioma, a malignant primary brain tumor, is notorious for its high incidence rate. However, the clinical application of temozolomide (TMZ) as a treatment option for glioma is often limited due to resistance, which has been linked to hypoxic glioma cell-released exosomes. In light...
Main Authors: | Guofu Li, Ziyu Xiong, Ying Li, Cong Yan, Yingying Cheng, Yuwen Wang, Jingwei Li, Zifeng Dai, Dongdong Zhang, Wenzhong Du, Chunyang Men, Changbin Shi |
---|---|
Format: | Article |
Language: | English |
Published: |
Springer
2024-04-01
|
Series: | Discover Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1007/s12672-024-00963-9 |
Similar Items
-
β-elemene combined with temozolomide in treatment of brain glioma
by: Xiaomin Zhang, et al.
Published: (2021-12-01) -
Temozolomide Chronotherapy in Glioma: A Systematic Review
by: Jason L. Jia, et al.
Published: (2023-02-01) -
Down-Regulation of CEND1 Expression Contributes to The Progression and Temozolomide Resistance of Glioma
by: Houjun Zhou, et al.
Published: (2023-04-01) -
Inhibition of DNA Repair in Combination with Temozolomide or Dianhydrogalactiol Overcomes Temozolomide-Resistant Glioma Cells
by: Shigeo Ohba, et al.
Published: (2021-05-01) -
Progress of temozolomide in the treatment of recurrent high-grade gliomas
by: Jin-duo LI, et al.
Published: (2013-12-01)